Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Telmisartan

Telmisartan

Angiotensin receptor blocker (ARB)

AdultARBHTNCV Risk

Indication

HTN β€’ CV-risk context

At a glance

INDICATIONS (CORE USE)

HTN with long half-life profile; CV-risk pathways in selected protocols.

ADULT DOSE (STANDARD)

PO START 20–40 mg daily, titrate to response.

MAX DOSE

Common max 80 mg/day.

Route

PO once-daily profile

PEDIATRIC DOSE

Not routine.

Do not miss

Must-not-miss safety points

Major warning

- Pregnancy contraindicated β†’ DO NOT use

Indications

USE IF: HTN and selected CV-risk ARB-based pathways. AVOID IF: pregnancy, bilateral renal artery stenosis, baseline hyperkalemia, or active hypoperfusion.

Primary

  • Hypertension

Secondary

  • CV-risk protocol-driven contexts

Dosing

STANDARD (ADULT PO)

Titrate with BP and lab safety gates.

ADULT DOSE

Typical start 20–40 mg daily; titrate as needed/tolerated.

PEDIATRIC DOSE

N/A

MAX DOSE

Common max 80 mg/day.

Practical Note

Long half-life supports adherence but does not reduce lab-check requirements.

Warnings

Clinical warnings

  • Lower cough/angioedema risk vs ACE inhibitors, but not zero
  • First-dose hypotension risk (especially HF / volume depletion)
  • Renal perfusion-dependent β†’ creatinine rise possible

Contraindications

  • Pregnancy
  • Bilateral renal artery stenosis (known/suspected)
  • Baseline K+ β‰₯5.5 mmol/L

Drug interactions

  • ACE inhibitor / aliskiren combination: avoid routine dual RAAS blockade (AKI, hyperkalemia, hypotension risk)
  • Potassium-sparing agents / supplements: hyperkalemia risk
  • NSAIDs β†’ ↑ AKI risk + ↓ ARB effect β€” avoid or monitor closely
  • Dual RAAS combinations increase harm risk without routine benefit.

Special populations

Pediatrics

Not routine.

Pregnancy

Pregnancy: contraindicated.

Lactation

specialist decision.

Renal impairment

Monitor creatinine/potassium early after start and escalation.

Hepatic impairment

Titrate cautiously with hepatic impairment.

Elderly

Start lower if orthostasis/falls risk is high.

Administration

PO daily with consistent timing and follow-up labs.

Monitoring

  • Recheck: - Check creatinine + potassium within 1–2 weeks after initiation - Recheck creatinine + potassium within 1–2 weeks after dose increase - Check earlier if CKD, elderly, volume depletion, or interacting drugs
  • Hold if:
    - HOLD if:
    - SBP <90–100
    - K+ β‰₯5.5 mmol/L
    - creatinine rise >30% from baseline
    - symptomatic hypotension
  • If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

A) Mild β†’ dizziness, hypotension, fatigue B) Moderate β†’ persistent hypotension, AKI trend, hyperkalemia C) Severe β†’ refractory shock, severe hyperkalemia, respiratory compromise

Immediate Actions

β€’ Airway + continuous monitoring (ABC, BP, telemetry) β€’ Hypotension β†’ IV fluids first-line β€’ Refractory hypotension β†’ early vasopressors β€’ Stop ARB immediately

Antidote

- No specific antidote - Supportive care + hemodynamic stabilization - Hyperkalemia treatment β†’ calcium + insulin/dextrose + potassium-shifting protocol

Decontamination

β€’ Recent oral ingestion β†’ activated charcoal if protected airway and early presentation (toxicology-guided)

Escalation

- Refractory hypotension β†’ ICU / vasopressors - Severe hyperkalemia / AKI β†’ nephrology + renal replacement planning if indicated

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Telmisartan identity: long half-life ARB with HTN/CV-risk profile nuance.

Clinical pearls

Do not confuse long half-life with lower risk of lab-related adverse events.

ARB safety

    Pharmacokinetics

    Long half-life supports durable once-daily BP coverage.

    Mechanism of action

    AT1 receptor blockade reduces vasoconstriction and aldosterone-mediated effects.

    Common brand names

    Saudi Arabia

    Micardis, Telmisartan

    Global

    (placeholder β€” verify local formulation)

    Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

    Country practice notes

    Global data (no country-specific data available)

    • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
    • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

    References

    Saudi Arabia

    • SFDA (Saudi Food & Drug Authority)
    • Saudi National Formulary / MOH (where available)

    International

    • WHO Model List of Essential Medicines (verify current edition)
    • US FDA or EU EMA product information (when national SmPC is unavailable)
    • ACC / AHA HF, HTN, CKD guidance
    • KDIGO CKD / albuminuria guidance
    • FDA / SFDA product labeling

    Do not miss

    • Pregnancy contraindicated β†’ DO NOT use
    • Hyperkalemia risk β†’ monitor potassium early
    • Creatinine rise / AKI risk (bilateral renal artery stenosis / volume depletion)
    • First-dose hypotension β†’ correct volume before starting